Should raising high-density lipoprotein cholesterol be a matter of debate?

Journal of Cardiovascular Medicine

Volumn 13, Issue 4, 2012, Pages 254-259

  Athyros, Vasilios G ^a   Katsiki, Niki ^b   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

cardiovascular events; cholesterol ester transfer protein inhibitors; fibrates; high density lipoprotein cholesterol; statins

Indexed keywords

ANACETRAPIB; DALCETRAPIB; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ATHEROGENIC DYSLIPIDEMIA; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NONHUMAN; REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; HYPOLIPIDEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84858773518     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283522422     Document Type: Review

References (60)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med 1977; 62:707-714. (Pubitemid 8110784)
2. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124 (Suppl):S11-S20.
3. Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
4. Chapman MJ, Ginsberg HN, Amarenco P, et al., European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32:1345-1361.
5. Athyros VG, Ganotakis E, Kolovou GD, et al. for the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative Group. Assessing The Treatment Effect in Metabolic Syndrome without Perceptible Diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011; 9:647-657.
6. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009; 338:b92-b100.
7. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010; 53:800-808.
8. Huxley RR, Barzi F, Lam TH, et al., Asia Pacific Cohort Studies Collaboration and the Obesity in Asia Collaboration. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation 2011; 124:2056-2064.
9. Barter PJ, Caulfield M, Eriksson M, et al., ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122. (Pubitemid 350146106)
10. Athyros VG, Kakafika A, Tziomalos K, Karagiannis A, Mikhailidis DP. Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended? Expert Opin Investig Drugs 2008; 17: 445-449 (Pubitemid 351578164)
11. Hu X, Dietz JD, Xia C, Knight DR, et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 2009; 150:2211-2219.
12. Katsiki N, Athyros VG, Mikhailidis DP. The DEFINE study: a bright future for CETP inhibitors? Expert Opin Investig Drugs 2011; 20:311-314.
13. Derks M, Anzures-Cabrera J, Turnbull L, Phelan M. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study. Clin Drug Investig 2011; 31:325-335.
14. Boden WE, Probstfield JL, Anderson T, et al., AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
15. Giugliano RP. Niacin at 56 years of age -time for an early retirement? N Engl J Med 2011; 365:2318-2320
16. Coronary Drug Project Investigators. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360-381.
17. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255. (Pubitemid 17208898)
18. Brown BG, Zhao XQ, Chait A, et al. Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study design. Can J Cardiol 1998; 14 (Suppl A):6A-13A.
19. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010; 210:353-361.
20. Nichols GA, Vupputuri S, Rosales AG. Change in high-density lipoprotein cholesterol and risk of subsequent hospitalization for coronary artery disease or stroke among patients with type 2 diabetes mellitus. Am J Cardiol 2011; 108:1124-1128.
21. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-418. (Pubitemid 29362514)
22. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622. (Pubitemid 28248586)
23. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-1574.
24. Tenenbaum A, Fisman EZ. If it ain't broke, don't fix it': a commentary on the positive-negative results of the ACCORD Lipid study. Cardiovasc Diabetol 2010; 9:24-29.
25. Tenenbaum A, Fisman EZ, Motro M, Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 2006; 5:20-28.
26. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-1245. (Pubitemid 17147964)
27. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85:37-45.
28. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260:641-651.
29. Goldenberg I, Goldbourt U, Boyko V, Behar S, Reicher-Reiss H, BIP Study Group. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial). Am J Cardiol 2006; 97:466-471. (Pubitemid 43190032)
30. Scott R, O'Brien R, Fulcher G, et al., Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009; 32:493-498.
31. Yetukuri L, Huopaniemi I, Koivuniemi A, et al. High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy. PLoS One 2011; 6:e23589.
32. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104:3046-3051. (Pubitemid 34014055)
33. Colquhoun D, Keech A, Hunt D, et al., LIPID Study Investigators. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. Eur Heart J 2004; 25:771-777. (Pubitemid 38647938)
34. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297:499-508. (Pubitemid 46220805)
35. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al., GREACE Collaborative Group. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2004; 20:627-637. (Pubitemid 38685006)
36. Athyros VG, Kakafika A, Karagiannis A, Mikhailidis DP. Statins and regression of coronary atherosclerosis correct. JAMA 2007; 297: 2197. (Pubitemid 47010890)
37. Kakafika A, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. High density lipoprotein cholesterol and statin trials. Curr Med Chem 2008; 15:2265-2270.
38. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91:2488-2496.
39. AssmannG, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 2003; 54:321-341. (Pubitemid 37386400)
40. Athyros VG, Kakafika AI, Papageorgiou AA, et al. Statin-induced increase in HDL-C and renal function in coronary heart disease patients. Open Cardiovasc Med J 2007; 1:8-14.
41. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
42. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57:728-734. (Pubitemid 38901488)
43. Shepherd J, Kastelein JJ, Bittner V, et al., TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008; 51:1448-1454. (Pubitemid 351471787)
44. Athyros VG, Mitsiou EK, Tziomalos K, Karagiannis A, Mikhailidis DP. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother 2010; 11:723-730.
45. Athyros VG, Karagiannis A, Ganotakis ES, et al., for the Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011; 27:1659-1668.
46. Fruchart JC, Sacks F, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008; 102 (10 Suppl):1K-34K.
47. Miyares MA. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors. Ann Pharmacother 2011; 45:84-94.
48. Cannon CP, Shah S, Dansky HM, et al., Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363:2406-2415.
49. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and co-administered with atorvastatin in dyslipidemic patients. Am Heart J 2009; 157:352.e2-360.e2.
50. Castro-Perez J, Briand F, Gagen K, et al. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J Lipid Res 2011; 52:1965-1973.
51. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient preb-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010; 51:3443-3454.
52. Fayad ZA, Mani V, Woodward M, et al., dal-PLAQUE. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel noninvasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011; 378:1547-1559.
53. Cao G, Beyer TP, Zhang Y, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res 2011; 52:2169-2176.
54. Rosenson RS. Functional assessment of HDL: moving beyond static measures for risk assessment. Cardiovasc Drugs Ther 2010; 24:71-75.
55. Niesor EJ. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Curr Opin Lipidol 2011; 22:288-295.
56. Van Linthout S, Spillmann F, Schultheiss HP, Tschöpe C. High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disorders. Curr Pharm Des 2010; 16:1504-1516.
57. Patel DC, Albrecht C, Pavitt D, et al. Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function. PLoS One 2011; 6:e22142.
58. Patel PJ, Khera AV, Jafri K, Wilensky RL, Rader DJ. The antioxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 2011; 58:2068-2075.
59. Tselepis AD, Tsoumani ME, Kalantzi KI, Dimitriou AA, Tellis CC, Goudevenos IA. Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy. J Thromb Haemost 2011; 9:2371-2378.
60. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23:370-378. (Pubitemid 351787103)